Abstract
BackgroundFoxM1 has been reported to be important in initiation and progression of various tumors. However, whether FoxM1 has any indication for prognosis in non-small cell lung cancer patients remains unclear.Methodology/Principal FindingsIn this study, FoxM1 expression in tumor cells was examined first by immunohistochemistry in 175 NSCLC specimens, the result of which showed that FoxM1 overexpression was significantly associated with positive smoking status (P = 0.001), poorer tissue differentiation (P = 0.0052), higher TNM stage (P<0.0001), lymph node metastasis (P<0.0001), advanced tumor stage (P<0.0001), and poorer prognosis (P<0.0001). Multivariable analysis showed that FoxM1 expression increased the hazard of death (hazard ratio, 1.899; 95% CI, 1.016–3.551). Furthermore, by various in vitro and in vivo experiments, we showed that targeted knockdown of FoxM1 expression could inhibit the migratory and invasive abilities of NSCLC cells, whereas enforced expression of FoxM1 could increased the invasion and migration of NSCLC cells. Finally, we found that one of the cellular mechanisms by which FoxM1 promotes tumor metastasis is through inducing epithelial-mesenchymal transition (EMT) program.ConclusionsThese results suggested that FoxM1 overexpression in tumor tissues is significantly associated with the poor prognosis of NSCLC patients through promoting tumor metastasis.
Highlights
Lung cancer has remained the leading cause of cancer-related death worldwide for several years
These results suggested that Forkhead box M1 (FoxM1) overexpression in tumor tissues is significantly associated with the poor prognosis of non-small cell lung cancer (NSCLC) patients through promoting tumor metastasis
To investigate whether the increased expression of FoxM1 was associated with various prognostic factors, patients were classified into two groups in terms of immunohistochemical staining for FoxM1 (Figure 1A, a–d): negative/weak expression and strong expression
Summary
Lung cancer has remained the leading cause of cancer-related death worldwide for several years. It has been reported to be over-expressed in a variety of tumors, including lung, liver and breast cancers [8,9,10,11,12,13], and played an essential role in development and progression in various malignancies [11,14,15,16]. We aim to determine the prognostic roles of FoxM1 overexpression in NSCLCs and further explore the mechanism by which FoxM1 could contribute to the metastasis of NSCLCs. FoxM1 has been reported to be important in initiation and progression of various tumors. Whether FoxM1 has any indication for prognosis in non-small cell lung cancer patients remains unclear
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
